Novo Nordisk – Jean-Paul Digy, Corporate Vice President, Africa Region
05.01.2015
Related Interviews
Italy / Gilead's Valentino Confalone on Eliminating Viral Hepatitis by 2030, HIV Pipeline Potential, & the Future of CAR-T
Gilead Sciences’ vice president and general manager for Italy, Valentino Confalone, outlines the company’s tumultuous pandemic journey in one of the first global epicentres; the role that Italy played in…
Italy / Gilead's Valentino Confalone on Eliminating Viral Hepatitis by 2030, HIV Pipeline Potential, & the Future of CAR-T
Can you begin by commenting on Gilead’s footprint in Italy, a country where the company has been present for just two decades? Even though it is relatively young, Gilead is…
Mohamed Mostafa – Vice President and General Manager Saudi Arabia &…
IQVIA Vice President and General Manager Saudi Arabia & Egypt Mohamed Mostafa gives his expert insights into the transformation of the Saudi pharma market in recent years, covering everything from…
Denmark / The Danish Foundation Model: Benefits Abound
Denmark’s four largest pharma companies – Novo Nordisk, Lundbeck, LEO Pharma, and ALK – are all at least partly owned by independent foundations, which means that their profits are divided…
Peptides / Technological Maturity Leading to Big Investments & Breakthroughs
With advances in technology, an increasing number of stable peptide-based therapeutics are being brought to market today across a wide range of therapeutic areas. Through expert insight, we explain why…
China / Fosun Sales up 20%; MNC Price Manoeuvres Lead to Growth; Bayer Sees ‘Golden Age’ Ahead
The latest news from Chinese pharma, including Fosun Pharma’s 2021 interim results; how AstraZeneca, Bayer, Eli Lilly, Merck & Co., Novartis, Novo Nordisk, and Sanofi have achieved China growth in…
